Category: Bio & Healthcare

Brokerage : Daishin Securities Analyst : Kahye Hong Investment Rating : BUY (Maintained) Target Price : KRW 2,000,000 (Maintained) Core Momentum : By acquiring Swiss peptide specialist PolyPeptide Group for approximately KRW 2.7 trillion, the company achieves rapid entry into the high-growth GLP-1 peptide market and secures a multi-regional global manufacturing network. 📊 1. [Valuation…

Read More “[Research] Samsung Biologics (207940) – Daishin Securities | Peptide Market Entry · Global Footprint Expansion · Modality Diversification / 2026-07-21” »

Brokerage : Hana Securities Analyst : Seona Kim (RA: Heekyung Lee) Investment Rating : BUY (Maintained) Target Price : KRW 580,000 (Maintained) Core Momentum : Market concerns dispelled as emerging competitors develop Enhanze biosimilars rather than novel enzymes, highlighting ALT-B4’s delivery differentiation potential and upcoming Qlex sales milestone confirmation via MSD’s Q2 earnings. 📊 1….

Read More “[Research] Alteogen (196170) – Hana Securities | ALT-B4 Differentiation Potential · Enhanze Biosimilar Concerns Dispelled · Qlex Revenue Visibility / 2026-07-15” »

Brokerage : Shinhan Securities Analyst : Hochul Lee (Senior Analyst), Minyong Eom (Analyst) Investment Rating : BUY (Maintained) Target Price : KRW 1,800,000 (Lowered) Core Momentum : Despite target price downward revision factoring in wage negotiation cost burdens and peer multiple compression, mid-to-long term growth drivers remain solid backed by Rockville commercial ramp-up in 3Q…

Read More “[Research] Samsung Biologics (207940) – Shinhan Securities | Wage Negotiation Factors · Rockville Ramp-up · Plant 6 Catalyst / 2026-07-01” »

Brokerage : IBK Securities Analyst : Yisoo Jung, CFA Investment Rating : BUY (Maintained) Target Price : KRW 2,090,000 (Maintained) Core Momentum : Despite temporary labor strike impacts, structural revenue visibility is expected to remain intact supported by favorable FX rates, revenue contribution from the Rockville site, and Plant 5 ramp-up in the second half….

Read More “[Research] Samsung Biologics (207940) – IBK Securities | Plant 5 Ramp-up · Resolution of Labor Risk · Annual Guidance Delivery / 2026-06-29” »

Brokerage : Daishin Securities Analyst : Kahye Hong (RA: Cherry Lee) Investment Rating : BUY (Maintained) Target Price : KRW 500,000 (Maintained) Core Momentum : Favorable outcomes in key US patent proceedings significantly ease IP risks, while discussions with 10+ potential partners under MTAs and surging Keytruda SC sales accelerate recognition of the remaining USD…

Read More “[Research] Alteogen (196170) – Daishin Securities | Key US Patent Risks Significantly Eased · New Licensing Catalysts · Keytruda SC Milestones / 2026-06-02” »

Brokerage : iM Securities Analyst : Jaewon Jeong Investment Rating : Buy (Maintain) Target Price : KRW 200,000 (Maintain) Core Momentum : Continued clinical data readouts across major ADC pipelines supported by over two years of R&D funding, alongside potential new global out-licensing deals 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities…

Read More “[Research] LigaChem Biosciences (141080) – iM Securities | Clinical Data · Pipeline Progress · Tech Transfer / 2026-05-21” »

Brokerage : Daishin Securities Analyst : Kahye Hong, Cherry Lee Investment Rating : BUY (Initiation) Target Price : KRW 280,000 (Initiation) Core Momentum : Structural EBITDA margin expansion into the upper-30% range following merger channel inventory resolution, backed by portfolio leverage and new CMO contracts 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market…

Read More “[Research] Celltrion (068270) – Daishin Securities | Merger Noise Resolution · Portfolio Expansion Leverage · CMO Revenue Visibility / 2026-05-19” »

Brokerage : Daishin Securities Analyst : Kahye Hong (RA: Cherry Lee) Investment Rating : Buy (Initiation) Target Price : KRW 500,000 (Initiation) Core Momentum : Clinically and commercially validated ALT-B4 platform drives ongoing big pharma licensing, while Keytruda SC commercialization secures long-term milestone/royalty cash flows alongside modality expansion into ADCs. 📊 1. [Valuation & Key…

Read More “[Research] Alteogen (196170) – Daishin Securities | Validated ALT-B4 Platform · Keytruda SC Milestones Accelerate · Coverage Initiation / 2026-05-19” »

Brokerage : Daishin Securities Analyst : Kahye Hong (RA: Chaeri Lee) Investment Rating : BUY (Initiation) Target Price : KRW 2,000,000 (Initiation) Core Momentum : Operating leverage maximization driven by Plant 5 full operation and US plant revenue integration, complemented by medium-to-long-term growth engines including Plant 6 construction and ADC modality expansion. 📊 1. [Valuation…

Read More “[Research] Samsung Biologics (207940) – Daishin Securities | Plant 5 Operation · Fixed-Cost Operating Leverage · Plant 6 Expansion / 2026-05-19” »

Brokerage : Shinhan Securities Analyst : Ho-chul Lee, Min-yong Eom Investment Rating : BUY (Maintained) Target Price : KRW 290,000 (Maintained) Core Momentum : Sustained earnings growth driven by expanding sales mix of new products, operating leverage from SG&A efficiency, US facility operations, and ramping global CMO orders 📊 1. [Valuation & Key Financial Metrics]…

Read More “[Research] Celltrion (068270) – Shinhan Securities | New Product Sales Expansion · Operating Leverage · Global CMO Contracts / 2026-05-15” »